Keros Therapeutics(NASDAQ) KROS

Keros Therapeutics makes medicines for people with blood and bone diseases. These treatments help patients whose bodies do not grow tissue correctly. The company targets rare conditions that have few medical options.

The Medicine Pipeline

• Elritercept (KER-050): Experimental protein therapy for treating cytopenias, or low blood cell counts, in patients with bone marrow disorders.
• Rinvatercept (KER-065): Candidate designed to improve muscle strength in patients with muscle-wasting diseases or nervous system disorders.
• KER-047: Small molecule drug candidate in early testing for patients suffering from anemia, which is a lack of healthy red blood cells.
• KER-012: Early-stage drug focused on lung diseases and conditions that cause bones to lose strength or density.

Partnerships and Milestones

• Partnered with Takeda in December 2024 to develop and sell elritercept globally, excluding parts of Asia.
• Dosed the first patient in a Phase 3 clinical trial for bone marrow disorders in July 2025.
• Initiated a second Phase 3 clinical trial to treat anemia in July 2026.
• Repurchased 10.2 million shares of common stock for $180.6 million in October 2025.

A Unique Scientific Approach

Keros specializes in a group of proteins that control the growth and repair of muscle, bone, and heart tissues. By focusing on these specific biological triggers, the company creates therapies that aim to restore normal tissue function in patients with chronic illnesses.

The Financial Scorecard

• Cash and cash equivalents totaled $257.6 million as of June 30, 2026.
• Net loss was $52.4 million for the six-month period ended June 30, 2026.
• Total revenue was $0.4 million for the six-month period ended June 30, 2026, compared to $229.4 million for the same period in 2025.
• Accumulated deficit reached $534.2 million as of June 30, 2026.

Bottom Line

Keros has moved from early research to late-stage clinical trials by leveraging partnerships with larger pharmaceutical firms to develop treatments for rare signaling disorders.